) has been revised to $22.48 / share. This is a decrease of 10.97% from the prior estimate of $25.25 dated April 7, 2026. The price target is an average of many targets provided by analysts. The ...

) has been revised to $25.25 / share. This is a decrease of 16.58% from the prior estimate of $30.27 dated March 25, 2026. The price target is an average of many targets provided by analysts. The ...

The investment seeks daily investment results, before fees and expenses, that correspond to two times (200%) the daily performance of the common shares of Sarepta Therapeutics, Inc. Under normal ...

Large pharmaceutical companies are racing to acquire biotech platforms addressing patent cliffs and next-generation therapeutic mechanisms, with depressed valuations across these five names creating ...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was ...